期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Ventana免疫组化检测非小细胞肺癌EML4-ALK融合基因及其结果判读难点分析 被引量：2

Detection of EML4-ALK gene rearrangement in NSCLC by Ventana IHC and the challenges for diagnosis
下载PDF
导出
摘要 目的分析Ventana免疫组织化学染色(IHC)检测非小细胞肺癌(NSCLC)组织中EML4-ALK融合基因的突变情况。解析Ventana IHC结果判读的难点和陷阱,为此项检测的开展提供参考。方法回顾性分析695份Ventana IHC检测NSCLC标本,对部分标本进行了实时定量PCR(qRT-PCR)对照研究。结果 EML4-ALK在腺癌中的突变率为8.78%,鳞状细胞癌中的突变率为4.49%,总突变率为8.48%。10例Ventana IHC为(-)和(+)标本qRT-PCR检测为阴性;5例Ventana IHC染色(+++)标本qRT-PCR检测均为阳性;5例Ventana IHC(++)标本qRT-PCR检测1例阳性。结论 EML4-ALK融合基因主要发生在肺腺癌。Ventana IHC检测结果存在判读难点和陷阱,判读需要谨慎。EML4-ALK IHC检测阳性(++)的需要qRT-PCR或其它方法进一步证实。 Objective To analyze the occurrence of EML4-ALK gene rearrangement in non-small cell lung cancer（ NSCLC）detected by Ventana immunohistochemical staining（ IHC）,as to explore the challenges of Ventana IHC and provide a reference for other hospital to carry out the examination. Methods In this study,659 cases of NSCLC were retrospectively analyzed and part of samples were checked by qRT-PCR. Results The occurrence rate of EML4-ALk in adenocarcinoma was 8. 78% and in squamous cell carcinoma was 4. 49%. Total occurrence in NSCLC was 8. 48%. All cases with IHC staining（-） and（ ＋） were confirmed negative mutation with qRT-PCR. Five cases with IHC staining（ ＋ ＋ ＋） were positive confirmed by qRT-PCR. One out of 5 cases with IHC staining（ ＋ ＋） was confirmed positive by qRT-PCR. Conclusion EML4-ALK predominantly occurred in lung adenocarcinoma. There are some challenges in diagnosis of Ventana IHC. All cases with IHC staining（ ＋ ＋） need to be verified by qRT-PCR or other methods.
作者 王璇 余波 马恒辉 周晓军 石群立 宋勇 王建东
机构地区 南京军区南京总医院病理科 南京军区南京总医院呼吸内科
出处 《临床肿瘤学杂志》 CAS 2015年第1期79-82,共4页 Chinese Clinical Oncology
关键词 非小细胞肺癌 Ventana免疫组织化学染色 EML4-ALK 基因重排 Non-small cell lung cancer Ventana immunohistochemical staining EML4-ALK Gene rearrangement
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib [J]. Clin Cancer Res, 2006, 12(3 Pt 1) :839-844.
  • 2Chang JW, Chou CL, I-Iuang SF, et al. Erlotinib response of EG- FR-mutant gefitinib-resistant non-small-cell lung cancer [ J ]. Lung cancer, 2007, 58(3) :414-417.
  • 3王锋,王琳,秦叔逵,华海清,陈映霞,刘秀峰,杨宁蓉.吉非替尼治疗非小细胞肺癌脑转移的临床观察[J].临床肿瘤学杂志,2013,18(6):515-520. 被引量：17
  • 4Shaw AT, Engelrnan JA. Cerltinib in ALK-rearranged non-small- cell lung cancer [ J ]. N Engl J Med, 2014, 370 ( 26 ) : 2537 -2539.
  • 5Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK- rearranged non-small-cell lung cancer[J]. N Engl J Med, 2014, 370(13) : 1189-1197.
  • 6Shen L, Ji HF. Ceritinib in ALK-rearranged non-small-cell lung cancer[J]. N Engl J Med, 2014, 370(26) :2537.
  • 7Vansteenkiste JF, Ceritinib for treatment of ALK-rearranged ad- vanced non-small-cell lung cancer[ J]. Future Oncol, 2014, 23: 1-15.
  • 8张绪超,陆舜,张力,王长利,程颖,李甘地,Tony Mok,Mok,黄诚,刘晓晴,王洁,王孟昭,张沂平,周建英,周晓燕,林冬梅,杨衿记,李慧,陈海泉,钟文昭,吴一龙.中国间变性淋巴瘤激酶（ALK）阳性非小细胞肺癌诊断专家共识（2013版）[J].中华病理学杂志,2013,42(6):402-406. 被引量：93

二级参考文献39

  • 1Soda M,Choi YL,Enomoto M,et al.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.Nature,2007,448(7153):561-566.
  • 2Wong DW,Leung EL,So KK,et al.The EML4 ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.Cancer,2009,115(8):1723-1733.
  • 3Shaw AT,Yeap BY,Mino-Kenudson M,et al.Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.J Clin Oncol,2009,27(26):4247-4253.
  • 4Shaw AT.Phase 3 randomized study of crizotinib versus pemetrexed or docetaxel chemotherapy in advanced,ALK-positive NSCLC (PROFILE 1007).35th ESMO,2012,abstract LBA1.
  • 5全国肿瘤防治研究办公室/全国肿瘤登记中心/卫生部疾病预防控制局.2009全国肿瘤登记年报.北京:军事医学科学出版社.2010.
  • 6Rikova K,Guo A,Zeng Q,et al.Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.Cell,2007,131 (6):1190-1203.
  • 7Mitsudomi T,Suda K,Tomizawa K,et al.Clinico-pathologic features of lung cancer with EML4-ALK translocation.J Clin Oncol,2010 (suppl):abstr 10598.
  • 8Zhang X,Zhang S,Yang X,et al.Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.Mol Cancer,2010,9:188.
  • 9Wu SG,Kuo YW,Chang YL,et al.EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wildtype EGFR.J Thorac Oucol,2012,7(1):98-104.
  • 10Rodig SJ,Mino-Kenudson M,Dacic S,et al.Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.Clin Cancer Res,2009,15(16):5216-5223.

共引文献108

同被引文献25

  • 1Heuckmann JM, HSlzel M, Sos ML, et al. ALK mutations con- ferring differential resistance to structurally diverse ALK inhibitors [J]. Clin Cancer Res, 2011, 17(23) :7394-7401.
  • 2Shaw AT, Yeap BY, Solomon B J, et al. Effect of crizotinib on o- verall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective anal- ysis[J]. Lancet Oncol, 2011, 12(11) : 1004-1012.
  • 3Chiari R, Duranti S, Ludovini V, et al. Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both ep- idermal growth factor receptor mutation and EMIA-ALK fusion gene[J]. J Clin Oncol, 2014, 32(9) :30-32.
  • 4Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers har- boring the fusion oncogene EML4-ALK [ J ]. Proc Nad Acad Sci USA, 2011, 108(18) :7535-7540.
  • 5Tamiya A, Okamoto I, Miyazaki M, et al. Severe acute interstitial lung disease after crizotinib therapy in a patient with EMIA-ALK-positive non-small-cell lung cancer [ J/OL ]. J Clin Oncol, 2013 [ 2015-02-10 ]. http://www, ncbi. nlm. nih. gov/ pubmed/23169500.
  • 6Govindan R. Hope without hype: EML4-ALK inhibition for treat- ment of lung cancer [ J ]. Lancet Oncol, 2011, 12 ( 11 ) : 983 -984.
  • 7Le Quesne J, Maurya M, Yancheva SG, et al. A Comparison of assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material[J]. J Thorac Oncol, 2014, 9(6) :769-774.
  • 8Wynes MW, Sholl LM, Dietel M, et 81. An international inter- pretation study using the ALK IHC antibody D5F3 and a sensitive detection Kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators [ J ]. J Thorac Oncol, 2014, 9(5) :631-638.
  • 9Soda M, Choi YL, Enomoto M, et al. Identification of the trans- forming EML4-ALK fusion gene in non-small-cell lung cancer [J]. Nature, 2007, 448(7153) :561-566.
  • 10Jin G, Jeon HS, Lee EB, et al. EMIA-ALK fusion gene in Kore- an non-small eell lung cancer[J]. J Korean Med Sei, 2012, 27(2) :228-230.

引证文献2

二级引证文献7

临床肿瘤学杂志
2015年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部